Evercore ISI raised the firm’s price target on Ascendis Pharma (ASND) to $220 from $205 and keeps an Outperform rating on the shares. The company is financed to profitability and Skytrofa weakness is “fully priced in,” say the analyst, who argues that it is “(finally) time to own the PTH launch.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ASND:
- Ascendis Pharma announces commercial availability of YORVIPATH in U.S.
- Ascendis Pharma Finalizes Key Collaboration with Novo Nordisk
- Ascendis Pharma announces results from New InsiGHTS tril of TransCon hGH
- Closing Bell Movers: RH soars 20% on earnings, guidance raise
- Ascendis Pharma’s TransCon hGH Receives FDA Review for Adult Use
Questions or Comments about the article? Write to editor@tipranks.com